IP Library Granted Patent US 10,112,925
Granted Patent B2
US 10,112,925 · App. 15/496,775 · Granted Oct 30, 2018

Methods for the preparation of charged crosslinkers

Inventors: Wei Li (Acton, MA); Robert Yongxin Zhao (Lexington, MA)
Assignee: IMMUNOGEN, INC.
C07D401/12C07D207/452C07D207/46C07D213/71C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,112,925
App. No.
15/496,775
Granted
Oct 30, 2018
Kind
B2
Abstract

Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.

Claims (26)

1. A process for the preparation of a compound represented by formula (V):

or a salt thereof, comprising the steps of:

a) reacting a compound of the following formula:

with sodium hydroxide to form a compound of formula (1a):

or a salt thereof;

b) reacting the compound of formula (1a) or a salt thereof with 1,2-di(pyridin-2-yl)disulfane (PySSPy) to form a compound of formula (2a):

or a salt thereof,

c) reacting the compound of formula (2a) or a salt thereof, with chlorosulfonic acid to form a compound of formula (IV):

or a salt thereof; and

d) reacting the compound of formula (IV), or a salt thereof, with N-hydroxysuccinimide in the presence of the coupling agent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form the compound of formula (V) or a salt thereof.

2. The process of claim 1 , wherein the sulfonating reaction of step c) is carried out in the presence of PySSPy.

3. The process of claim 2 , wherein about 0.5 equivalent of PySSPy is present.

4. The process of claim 1 , wherein in step d) the compound of formula (IV), or a salt thereof, is reacted with N-hydroxysuccinimide in the presence of a base to form a salt of the compound of formula (V) followed by purifying the salt of the compound of formula (V) by crystallization in the presence of an acid to form the neutral form of the compound of formula (V).

5. The process of claim 4 , wherein the base is diisopropylethylamine (DIPEA).

6. The process of claim 4 , wherein the acid is HCl.

7. The process of claim 5 , wherein the acid is HCl.

8. The process of claim 4 , wherein the crystallization is carried out in a mixture of an organic solvent and water.

9. The process of claim 6 , wherein the crystallization is carried out in a mixture of an organic solvent and water.

10. The process of claim 7 , wherein the crystallization is carried out in a mixture of an organic solvent and water.

11. The process of claim 1 , wherein 3.8 equivalents, 5.6 equivalents, 5.7 equivalents, or 6.0 equivalents of chlorosulfonic acid relative to the compound of formula (2a) is used in step c).

12. The process of claim 1 , wherein step c) of the method comprises: i) reacting the compound of formula (2a) with 3 equivalents of chlorosulfonic acid relative to the compound of formula (2a) at a temperature between 75° C. and 80° C., ii) adding an additional 1.33 equivalents of chlorosulfonic acid to the reaction mixture; and iii) adding a further 1.33 equivalents of chlorosulfonic acid.

13. The process of claim 1 , wherein the reaction between the compound of formula (2a) or a salt thereof, and chlorosulfonic acid in step c) is carried out between 70° C. and 90° C.

14. The process of claim 13 , wherein 3.8 equivalents, 5.6 equivalents, 5.7 equivalents, or 6.0 equivalents of chlorosulfonic acid relative to the compound of formula (2a) is used in step c).

15. The process of claim 13 , wherein step c) of the method comprises: i) reacting the compound of formula (2a) with 3 equivalents of chlorosulfonic acid relative to the compound of formula (2a) at a temperature between 75° C. and 80° C., ii) adding an additional 1.33 equivalents of chlorosulfonic acid to the reaction mixture; and iii) adding a further 1.33 equivalents of chlorosulfonic acid.

16. The process of claim 2 , wherein the reaction between the compound of formula (2a) or a salt thereof, and chlorosulfonic acid in step c) is carried out between 70° C. and 90° C.

17. The process of claim 3 , wherein the reaction between the compound of formula (2a) or a salt thereof, and chlorosulfonic acid in step c) is carried out between 70° C. and 90° C.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2017
From: LI, WEI; ZHAO, ROBERT YONGXIN
To: IMMUNOGEN, INC.
Reel/Frame 042784/0034 →
Continuity (6)
Continuation 14969720 · Dec 15, 2015
Continuation 14539361 · Nov 12, 2014
Continuation 14045151 · Oct 3, 2013
Division 13315005 · Dec 8, 2011
Provisional Application 61421357 · Dec 9, 2010
Related Publication 20170327486A1 · Nov 16, 2017